Geron Corp (GERN) News

I can’t believe it is doing the same thing it did last time it went into the mid 3’s… it went back to the low 170’s …… oh that’s right no earth shattering news left !

Well you are getting to see the weakness of gern … everyone is going to take all of their money out of this because they are afraid of the future of this company .i said this week was going to be very important if it is able to go up it may have been a different story .

GERN has been public going back to the prior century
I should paste a very long term chart instead of a one year
New 52 hi

went from 3.30 to 3.60 this week...good week!

Next week will be a big week … it will prove it’s worth

perfect "cup and handle" (stock chart buy signal) seen in the one year stock chart view for Geron Corp? Very bullish on this stock...load up boys and girls and hang on!

Looks like it happen today!!

Looking good. Nice CEO chat yesterday.

"Very clear with their comfort level in managing cytopenias..."

Medical Affairs / Commercial organization in place.

If OS hits in MF it'll be transformational. IA 1/2 of 2025.

Cash good into 2026

We haven't been this high since June of last year. Over 10 months ago...I believe we reach a new 52 week high (3.74) by tomorrow.

Just 13 cents off a year high. Not hearing to much bashing now. Somebody has heard something

LOL!!!

So, by your reckoning, if you are so smart then why are you still here?

Oh bullshit … this close to fda approval this should be climbing everyday the only problem is no one has enough confidence in what the approval outcome is going to be … especially the powers to be !

Dont expect much movement until FDA approval in June...then expect buyout within 90 days of approval.

Target $6 to $8

Oh ya going up two days in a row would just be too much to ask for . So manipulated !

Oh ok no news so down it goes this will be back under 2 in less than a month … joke !

What a surprise no big ground shaking news and it’s down ….cant beat a manipulated stock

I have never seen a company that needs to have earth shattering news every day yo go up or it goes down … criminal!

It’s going back below 3 looking to buy options at the right price like everyone else. Hard getting the right price. Cheers s

So much for seeing how it plays out. LOL.

Get ready. This is going to turn and fall. It’s over bought and the approval even if it goes thru which it will not. Will do nothing for the value of this company. Cheers.

I hear you. Let’s see how it plays out. Happy trading and good luck.

12 to 2 tells me they've got side effects under control. Can you imagine if Imetelstat can target telomerase in most all cancers to simply inhibit the proliferation of malignant stem and progenitor cells, while in combo with other therapies! It'd be a game changer.

I hear you. Just don’t like all the side effects. I’m not sure it will get the final ok. Cheers.

It's far too important a therapy to shelve. They have any side effects under control. For any serious therapy side effects are almost necessary, unfortunately.

They are not going to be approved. There is too much risk and side effects. More bad news to come.

There won’t be anything keeping this up … everyone will take anything gains they have and run

If any bad news about trials comes out shareholders will be in bad shape, no matter. Just as long as the street thinks a buyout could be in the works the price should hold up well. But this is Geron we're talking about so, I give you that.

OMG the ignorance of this company releasing 42 million in shares. This is so bad. The price will be pushed down every time the company sells. It any bad news about trails come out we are in real bad shape. It’s a bloodbath. Cheers

Nah. Maybe to $3 for a little bit. This is exactly what's to be expected upon imminent approval. I have no issues with a raise like this. Plus Geron's now a takeover target so the cash will be reflected in the purchase price.

>>The gross proceeds to Geron from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $150.0 million. Geron currently intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and current and noncurrent marketable securities, to fund the potential commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the U.S, and potential launch and commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the EU, subject to receipt of regulatory approvals, as well as continued development and potential regulatory submissions for imetelstat in relapsed/refractory myelofibrosis. Geron intends to use the remaining proceeds, if any, for working capital and general corporate purposes.

More shares being issued. Dilution of the shares. This is bad. Wait and see. Down she goes. Getting out here.

If that be the case, then why are so many capitalist groups are picking up the new shares and warrants?

Going down back to 2 dollars. They make no money. Cheers.

Not really, I'm still way up, with the decision from FDA still comin, I expect a great return. Thanks again

Your welcome big bambino …. Pretty short lived though isn’t it ? 1 day!!

STAT News' Adam Feuerstein Publishes "I Was Wrong About Geron's Blood Cancer Drug. Now, Is It A Takeover Target?"; Shares See Volume
BENZINGA 9:08 AM ET 3/18/2024
Symbol Last Price Change
GERN 3.205up -0.155 (-4.6131%)
QUOTES AS OF 09:49:54 AM ET 03/18/2024

https://www.statnews.com/2024/03/18/geron-blood-cancer-drug-takeover-target/

I was wrong about Geron(GERN). For years, I've believed -- and declared publicly -- that Geron's(GERN) effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.

On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat's favor, concluding the drug's benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.

$GERN Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z

Spike, I want to thank you for your persistent bashing of Gern. As it dipped and you bashed, even when the numbers showed it's path, I continued to add.

Should be a $5b market cap. Suspect this is a game changing therapy just as long as the side effects can be controlled.

Yes!!!

Just opened

tomorrow should be FUN 😁

Vote 12 - 2 in favor Benefit outweigh risk.

Listening to this, I believe the FDA will approve.

FDA ODAC Live meeting...

FDA news pending ….going way up or down this morning….one way or the other …..major drug in question

T1 halt….

Wow is this puking ! Unbelievable

Thank You

It actually would be funny if it was not so sad

UPDATE 2-US FDA staff raises concerns on Geron's blood disorder drug
8

002722.SZ
+1.24%
Christy Santhosh and Pratik Jain
Updated Tue, March 12, 2024 at 9:55 AM CDT
In this article:

002722.SZ
+1.24%

(Adds statement from staff reviewers paragraph 5 onwards, analyst comment in paragraph 9)

By Christy Santhosh and Pratik Jain

March 12 (Reuters) - The U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's blood disorder drug provided a clear benefit to patients in a late-stage trial and raised multiple safety concerns with the treatment.

Geron is seeking approval of the injectable drug, called imetelstat, for treating transfusion-dependent anemia in patients with a group of blood cancers called myelodysplastic syndromes (MDS).

The drug, if approved, will compete with Bristol Myers Squibb's Reblozyl, which has been approved by the FDA for the same disease indication.

Last year in January, Geron CEO John Scarlett told Reuters that the company anticipates a peak market potential of $1.2 billion for imetelstat in the United States and some key EU countries by 2030.

While Geron's drug met the main goal of increasing independence from transfusion at eight weeks in a late-stage study, the FDA's staff said the "clinical meaningfulness" of the data was unclear.

"The general consensus among MDS experts has been that only a 16-week or longer period of transfusion independence is clinically meaningful," the agency's staff said ahead of a meeting of FDA's independent advisers scheduled for Thursday.

The agency said that while the drug is believed to work by treating the underlying cancer, the study did not show a "disease-modifying effect" in either extending survival or helping drive disease remission.

It also highlighted a high rate of low red blood cell count in the late-stage study.

Wedbush analyst Robert Driscoll said it was expected that the briefing documents would lean negative and added that Geron will be able to provide a strong case against the points made by the FDA. (Reporting by Christy Santhosh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)